Flying in from San Diego, CA, we are honored to have Dr. Paul Pockros join us at the #LiverUpdate as our keynote speaker for the State-of-the-Art Lecture on Hepatitis C: From Discovery to Elimination! If you missed @AASLD #TLM23, join us on December 1st to get caught up!
A truer statement has never been uttered! Please support @AASLDFoundation and it’s mission to advocate, support and advance research in hepatology! @AASLDtweets #TLM23
The 2023 #TLM23 @AASLDtweets version of #HCC shark tank is in progress @docamitgs @NDP1001 @AndrewMMoon
After extensive discussion, AASLD, EASL & others have adopted a new naming system for fatty liver disease, intended to emphasize the underlying metabolic cause & reduce stigma by de-emphasizing alcohol & retiring "fatty". #TLM2023 #TLM23
www.hepmag.com/article/name...
Get your gear at the @AASLDtweets hub! Socks, mugs and more for that liver lover in your life! #TLM23
Animated debate on the merits of liver transplantation in persons with alcohol associated hepatitis. @JoseeLynch @juanpabloarab @drbobbybrown @TiffanyWuMD @mandrekp @AASLDtweets #TLM23
@US_FDA statement is that they will not mandate sponsors to use the new SLD nomenclature and use terms interchangeably @AASLDtweets #TLM23
@US_FDA communication to stakeholders and sponsors is that they will not mandate use of new nomenclature and are ok with using MASLD/ NAFLD and MASH/NASH interchangeably. @AASLDtweets #TLM23
@HannesHagstrom presents data suggesting you should just swap existing ICD codes for #NAFLD to #MASLD and #NASH to #MASH and create a new category for #MetALD
People will widely adopt when they can bill appropriately so this is important to address ASAP. @AASLDtweets #TLM23
On behalf of editors of the hepatology family of journals @HEP_Journal @HepCommJournal Dr. Greg Gores states the journals will not publish papers that do not use the new #MASLD #MASH nomenclature @AASLDtweets #TLM23
Live from Boston! Prof Sanyal presents data from the NIMBLE cohort showing very few persons would be reclassified as having cryptogenic steatosis or cirrhosis based on new nomenclature @AASLDtweets #TLM23
Space is at a premium for the @AASLDtweets #TLM23 PGC with experts debating hot topics ranging from SBP prophylaxis to controversies in the diagnosis of #HCC
A great @AASLDtweets annual tradition is the @CLDFoundation abstract review. Thank you for continuing to be the only CME accredited educator solely focused on educating about liver disease. #TLM23
Boston bound and looking forward to tweeting on topics of interest and connecting with friends and colleagues! @AASLDtweets #TLM23
#TLM23 is only a week away! Looking forward to meeting many #livertwitter peeps I have never interacted with in person at the @AASLDtweets liver meeting in Boston!
